Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Affiliated Clinical Research Inc

Neither a doctor nor a teaching hospital

Research payments

$4,492,033

333 payments

Through program year 2025, Affiliated Clinical Research Inc is reported as receiving $4,492,033 in research payments, across 333 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $532,567 30
2024 Research $406,000 53
2023 Research $963,072 45
2022 Research $196,294 16
2021 Research $453,763 71
2020 Research $211,559 36
2019 Research $1,728,779 82

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $1,070,866 9 payments
  2. Mylan Inc. $691,951 38 payments
  3. AbbVie, Inc. $579,115 78 payments
  4. Regeneron Pharmaceuticals, Inc. $544,570 33 payments
  5. Sumitomo Pharma America, Inc. $502,861 61 payments
  6. Novartis Pharmaceuticals Corporation $438,222 7 payments
  7. Noven Pharmaceuticals, Inc. $278,578 17 payments
  8. Exeltis, USA Inc. $136,219 22 payments
  9. Mitsubishi Tanabe Pharma Development America, Inc. $66,520 3 payments
  10. Allergan Inc. $61,674 18 payments
Studies the money was for Research payments · program years 2019–2025
  1. Mr-100A-01-Td-3001-A Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety $691,951 38 payments
  2. A Phase 3 Randomized Doubleblind Activecontrolled Multicenter Study of the Longterm Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip Or Knee $683,976 4 payments
  3. Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo and Nsaid Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee Or Hip $544,570 33 payments
  4. A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $260,529 15 payments
  5. A Phase 3 Randomized Double Blind Placebo and Activecontrolled Multicenter Parallelgroup Study of the Analgesic Efficacy and Safety of Tanezumab in Adult Subjects With Chronic Low Back Pain $241,921 4 payments
  6. Long-Term Safety Study of Elagolix in Combination With Estradiol;Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women $215,850 1 payment
  7. A Randomized, Four-Arm, Placebo-Controlled, Participant, Investigator and Sponsor-Blinded Study Investigating the Safety, Tolerability and Efficacy of Intra-Articular Canakinumab Followed By Intra-Articular Lna043 in Patients With Knee Osteoarthritis $204,653 3 payments
  8. A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy $169,409 2 payments
  9. A Phase 3 Randomized Doubleblind Placebocontrolled Multicenter Study of the Analgesic Efficacy and Safety of A Dose Titration Regimen for the Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip Or Knee $144,968 1 payment
  10. A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles $136,219 22 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record